clinical trial · NCT07160725
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb·phase2·recruiting·n = 315
Solid TumoursBMS-986517
brief summary
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
started
Oct 15, 2025
primary completion
Jul 31, 2028
completion
Aug 1, 2028
last updated
May 15, 2026
official title
A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol